AstraZeneca pushes back OS readout on MYSTIC to H2; Anthera shares obliterated in repeat PhIII flop
2018-03-12
→ The much-anticipated overall survival data of AstraZeneca’s $AZN pivotal lung cancer trial will be delivered later than expected, the UK drugmaker announced this morning. Investors will now have to wait until the second half of 2018 for the final analysis of Imfinzi’s impact on OS, instead of the first half. The results from the MYSTIC trial remains a major catalyst after the checkpoint inhibitor failed to meet the primary endpoint of progression-free survival (PFS), sending a shock wave to AstraZeneca’s stock prices last July. The trial tests Imfinzi both as a monotherapy and in combination with tremelimumab against chemotherapy in first-line non-small cell lung cancer, an all-important arena in the battle for checkpoint drug dominance.
→ If at first you don’t succeed in biotech, maybe you should just cut your losses and move on. That lesson may be top of mind today for Anthera $ANTH after researchers reported that its lead drug Sollpura failed a repeat Phase III study for cases of exocrine pancreatic insufficiency caused by cystic fibrosis. The biotech had already felt the sting of investor dissatisfaction when an earlier Phase III also failed. This time scientists had hoped that more agressive dosing would fix the problem. It didn’t. Anthera’s shares were eviscerated, dropping 82% and leaving the stock deep in penny stock territory.
→ Malvern, PA-based Realm Therapeutics says that their Phase II study of a new therapy for allergic conjunctivitis failed, forcing the biotech to dump the drug. PR013 was a topical ophthalmic solution. Realm’s shares (AIM: $RLM) took a dive on the news.
→ Oxford University spinout OxSyBio stepped out today with a £10 million ($13.9 million) Series A round, joining the increasingly crowded space of “tissue bioprinting” startups. This one is developing a 3D printer technology that can print biological materials, with the ultimate goal of making therapeutic tissues for patients. This is not unlike the goals of San Diego’s more mature Organovo, or the relative newcomer StemoniX. OxSyBio was founded back in 2014 on research conducted in the lab of Professor Hagan Bayley, the founding academic behind Oxford Nanopore Technologies. The new financing round was led by Woodford Investment Management alongside new and existing backers, according to a company statement.
With additional reporting by Brittany Meiling and Amber Tong.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。